Phase IV Multi-Year Efficacy Study of Fluzone High-Dose Trivalent Vaccine Compared With Fluzone Vaccine In Adults 65 Years of Age or Older

StatusFinished
Effective start/end date17/09/0931/08/10

Funding

  • Sanofi Pasteur, Inc.: $205,100.00

Keywords

  • Biotechnology & Drug Development, Infectious Diseases